Tumor analysis

Immune response to ovarian cancer may predict survival

A group of international cancer researchers led by investigators from Mayo Clinic and University of New South Wales Sydney has found that the level of a type of white blood cell, called tumor-infiltrating lymphocytes, present in the tumors of patients with high-grade ovarian cancer may predict a patient’s survival.

Cancer in ovary of woman illustration
Source: Shutterstock/BlueRingMedia

“We know that a type of tumor-infiltrating lymphocyte called cytotoxic CD8 are present in the tumors of patients with high-grade ovarian cancer,” says Matthew Block, M.D., Ph.D., a Mayo Clinic oncologist who co-led the research team with Ellen Goode, Ph.D., of the Mayo Clinic Cancer Center Genetic Epidemiology and Risk Assessment Program. “However, little was known about the role in fighting high-grade ovarian cancer, compared to other clinical factors.”

The higher the level of cytotoxic CD8 tumor-infiltrating lymphocytes in a tumor, the better the survival

Matthew Block

To help answer this question, researchers studied more than 5,500 patients from nine different countries, including 3,196 with high-grade ovarian cancer. Researchers found that patients with high-grade ovarian cancer showed the most infiltration with tumor-infiltrating lymphocytes, which were associated with longer overall survival.

“This study shows the higher the level of cytotoxic CD8 tumor-infiltrating lymphocytes in a tumor, the better the survival for patients with high-grade ovarian cancer,” says Dr. Block. “Developing a better understanding of factors that increase cytotoxic CD8 tumor-infiltrating lymphocytes will be the key to developing treatments to achieve better outcomes in treating patients with high-grade ovarian cancer. “This is by far the largest study of this type and would not have been possible without scientists from North and South America, Europe and Australia all working together,” says Susan Ramus, Ph.D., University of New South Wales Sydney.


Source: Mayo Clinic

15.10.2017

Read all latest stories

Related articles

Photo

Tumor-associated macrophages

Immune cells key to predicting cancer outcomes

Scientists have identified key changes in immune cells within cancerous tumours that could help improve the development of treatments. The study, which has been published in the journal Cancer Cell,…

Photo

In situ vaccination

Turning tumors into cancer vaccine factories

Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells…

Photo

PARG inhibitors

New class of drugs could treat ovarian cancer

A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing. The Cancer Research UK and Wellcome Trust funded study,…

Related products

Beckman Coulter – Anti-Mullerian Hormone (AMH)

Immunochemistry

Beckman Coulter – Anti-Mullerian Hormone (AMH)

Beckman Coulter, Inc.
Beckman Coulter – phi (Prostate Health Index)

Immunochemistry

Beckman Coulter – phi (Prostate Health Index)

Beckman Coulter, Inc.
Beckman Coulter – Vitamin D Assay

Immunoassays

Beckman Coulter – Vitamin D Assay

Beckman Coulter, Inc.
DiaSys Diagnostic Systems - BioMajesty JCA-BM6010/C

Clinical chemistry

DiaSys Diagnostic Systems - BioMajesty JCA-BM6010/C

DiaSys Diagnostic Systems GmbH
DiaSys Diagnostic Systems - respons910

Clinical chemistry

DiaSys Diagnostic Systems - respons910

DiaSys Diagnostic Systems GmbH